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The first tenet of medicine, “primum non nocere” or “first, do no harm”, is not always compatible with oncological
interventions e.g., chemotherapy, targeted therapy and radiation, since they commonly result in significant toxicities.
One of the more frequent and serious treatment-induced toxicities is mucositis and particularly oral mucositis (OM)
described as inflammation, atrophy and breakdown of the mucosa or lining of the oral cavity. The sequelae of oral
mucositis (OM), which include pain, odynodysphagia, dysgeusia, decreased oral intake and systemic infection,
frequently require treatment delays, interruptions anddiscontinuations that not only negatively impact quality of life but
also tumor control and survivorship. One potential strategy to reduce or prevent the development of mucositis, for
which no effective therapies exist only best supportive empirical care measures, is the administration of agents
referred to as radioprotectors and/or chemoprotectors, which are intended to differentially protect normal but not
malignant tissue from cytotoxicity. This limited-scope review briefly summarizes the incidence, pathogenesis,
symptoms and impact on patients of OM as well as the background and mechanisms of four clinical stage
radioprotectors/chemoprotectors, amifostine, palifermin, GC4419 and RRx-001, with the proven or theoretical
potential to minimize the development of mucositis particularly in the treatment of head and neck cancers.
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The term “Medical Machiavellianism” [1] has been coined to describe
the predominant ‘first, do harm to do good’ oncologic paradigm of
chemotherapy, targeted therapy and radiation administration in
which toxicity and benefit are inextricably linked; by contrast,
anti-Medical Machiavellianism occurs when toxicity far exceeds
benefit.
A quintessential ‘anti-Medical Machiavellian’ iatrogenic toxicity,
for which no established effective treatment exists and from which
patients tend to suffer greatly, is mucositis and particularly oral
Table 1. World Health Organization (WHO) Oral Mucositis Scale (modified from [10])
Grade 1 (mild) Oral soreness, erythema
Grade 2 (moderate) Erythema, ulcers, but oral intake not prevented
Grade 3 (severe) Oral ulcers interfering with oral intake and requiring liquids only
Grade 4 (life-threatening) Oral ulcers to the extent that oral alimentation is impossible
772 Clinical Chemoradioprotection for Oral Mucositis Oronsky et al. Translational Oncology Vol. 11, No. xx, 2018mucositis (OM), a term introduced in the late 1980s [2], involving
dose-limiting inflammation and ulceration of the oral cavity during
chemotherapy, targeted therapy [3], and radiation treatment [4].
While treatment-related mucositis may occur throughout the
gastrointestinal tract, this review is focused on OM, which is
mucositis that involves the oral cavity, oropharynx, and hypopharynx.
The debilitating sequelae of OM, which include pain, odynodys-
phagia, dysgeusia, dehydration, malnutrition, and systemic infection
[5–7], are expensive not only in terms of the direct costs to manage them
but also in terms of reduced quality of life and survival secondary to dose
reduction or therapy discontinuation.
OM occurs in up to 40% of cancer patients that receive
chemotherapy and approaches 100% in the treatment of head and
neck cancers [8]; the symptoms, which vary in severity from Grade 1
(mild with redness and soreness) toGrade 4 (life-threatening preventing
oral intake) (See Table 1), begin after a cumulative exposure to 15 Gy
and worsen markedly if the total dose exceeds 60 Gy [9].
The pathogenesis of mucositis is related to direct mucosatoxicity
from ionizing radiation (IR) and several anticancer agents such as
methotrexate, doxorubicin, 5-fluorouracil, busulfan, bleomycin, cis-
platin, carboplatin, etoposide, EGFR inhibitors, and selected tyrosine
kinase inhibitors [11] in combination with infections, exacerbated by
neutropenia, that develop on the damaged mucosa [12]. Methotrexate
and etoposide, in particular, are secreted in saliva, which leads to an
increased risk of direct mucositis [13].
While evidence of a direct causal link between mucositis and
neutropenia is not definitive, the possibility that it is a contributory
factor is suggested by a) reduced duration and severity of the OM
with topical and systemic GM-CSF treatment (although this data is
contradictory [14]) b) predisposition to mucositis with lowFigure 1. Neutrophil and Macrophage Polarizationneutrophil counts (b400 cells/μL) c) high incidence of microbial
infections during neutropenia since perturbation of the mucosal
barrier results in a portal of entry for pathogens and
neutrophil-depleted patients are less able to clear these pathogens d)
recovery of the mucosa in tandem with white cell recovery, all of
which implies that depletion of neutrophils leads to impaired wound
healing and that neutrophil repopulation particularly during the
recovery phase accelerates repair [15].
Like macrophages, neutrophils are highly plastic cells, capable of
dynamically switching between twomain states, N1, inflammatory, and
N2, pro-repair, in a context- and time-dependentmanner. Immediately
following radiation exposure, neutrophils and macrophages adopt N1
and M1 activated phenotypes, respectively, in part due to the
recognition and clearance of chemoradiation-induced apoptotic and
necrotic cells [16], resulting in prolific expression of pro-inflammatory
cytokines such as TNF and IL-6; however, as the wound matures and
the dead cells, debris and pathogens are progressively cleared, the ratio of
pro-inflammatory N1/M1 to pro-repair N2/M2 changes in favor of the
latter, resulting in high expression levels of the anti-inflammatory
cytokine, IL-10, and growth factors such as PDGF and TGF-β [17]
with subsequent deposition of new extracellular matrix, reepithelializa-
tion and neovascularization. (Figure 1)
It is this time- and wound stage-dependence of macrophage and
neutrophil function and polarization during the repair process,
which probably accounts for the contradictory results with G-CSF
(some studies show a positive effect and some no effect), since an
increased influx of neutrophils and macrophages may be harmful to
resolution in the earlier stages and helpful in later ones. In any case,
due to these conflicting results in mucositis, the use of G-CSF is
not recommended.
Traditional management of OM, which is mainly anecdotal rather
than evidence-based, may consist of ice chips (oral cryotherapy), oral
cavity care, multi-agent topical rinses and lozenges (e.g., Magic
Mouthwash and PTA lozenges) hydration, nutritional support,
systemic pain relief, low-level laser, mouth coating agents like
sucralfate, growth colony stimulating factor (G-CSF) and infection
surveillance and treatment. Since no single therapy or combination of
therapies have been shown to be successful in OM, one strategy is toDuring the Early and Late Stages of Mucositis
Table 2. Risk Factors for OM
Treatment -specific Patient -specific
Type of chemotherapy in particular
5-FU, methotrexate and etoposide
Tobacco abuse
Higher doses and continuous infusion
especially with 5-FU
Neutropenia
Age
Concomitant radiation therapy Nutritional status
Radiation administered directly to
the head and neck
Gender
Oral health and hygiene
Presence of dentures
Low body mass index
Decreased renal function
Comorbid conditions e.g., diabetes
Genetic polymorphisms or deficiencies in drug
metabolizing enzymes
Vitamin B12/folic acid deficiencies
Salivary dysfunction
Concomitant medications e.g., anticholinergics and
antidepressants that decrease salivary flow
Higher levels of oral microflora
Previous cancer treatment
Immune dysfunction from an underlying disease state
e.g., ulcerative colitis, rheumatoid arthritis, lupus etc.
Epigenetic factors
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there are only three with clinical data, amifostine, palifermin and
RRx-001. In this review, the incidence, pathogenesis, symptoms andFigure 2. Flow chart of managemimpact on patients of OM are briefly summarized along with the
background on these three chemoradioprotectors and the proposed
mechanisms for their beneficial effects.
Incidence and Risk Factors of OM
In general, while mucositis occurs in up to 40% of patients treated with
conventional chemotherapy, more than 70% of patients that undergo
conditioning therapy for bone marrow transplantation [18] and virtually
all head and neck patients that receive simultaneous radiochemotherapy
[19], its severity is highly variable and depends on treatment- and
patient-specific risk factors (see Table 2). Of the two, treatment-related
risk factors, which include dose, location, duration of chemotherapy, and
concomitant use of chemotherapy and radiation, are the more impactful;
however, since several patient-specific risk factors are potentially
modifiable through preventative actions (e.g., poor oral hygiene, the
presence of dental appliances, diabetes, oral lesions, malnutrition,
neutropenia, folic acid/vitamin B12 deficiencies, concomitant medica-
tions, salivary hypofunction/xerostomia [20], tobacco use etc.) they
should be identified and addressed before the start of therapy by both an
oncologist and a dentist. Other less modifiable patient risk factors include
age, gender, body mass index, underlying immune dysfunction,
polymorphisms and deficiencies in drug metabolizing enzymes and
other epigenetic and genetic factors, which affect the expression or activity
of cytokines and transcription factors, such as TGF-β, NF-κB and p53
and genes such as COX-2 and MMPs, all of which are implicated in the
development of mucositis [21].ent Adapted from Napenas [64]
Table 3. The 5-phases of Oral Mucositis Adapted from Sonis [27]
Phase I—Initiation Chemotherapy or radiation-induced reactive oxygen species (ROS)
and lipid peroxidation results in DNA damage, release of
pathogen-as soc ia ted molecu lar pa t te rn (PAMP) and
damage-associated molecular pattern molecules (DAMPs) and
cellular apoptosis
Phase II—Signaling ROS stimulate the NF-kB pathway, which induces production of
proinflammatory cytokines (TNF-α, IL-1β, IL-6)
Phase III – Amplification Proinflammatory cytokines trigger tissue injury, apoptosis, vascular
permeability, and activation of cyclooxygenase-2
Phase IV—Ulceration Ulceration occurs, which serves as a portal of entry for microorganisms.
The presence of bacteria activate macrophages and neutrophils to
further produce proinflammatory cytokines
Phase V—Healing Signaling from the submucosa promotes epithelial migration,
proliferation and differentiation
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of Life
While treatment-related nausea, vomiting and cytopenias are the most
common adverse events in oncology, mucositis has emerged as the most
significant according to an NCCN task force [22]. Its adverse physical,
social and psychological impacts on patients are legion and include the
need for total parenteral nutrition (TPN), higher risk of systemic
infections, increased use of antifungals and opioid analgesics, increased
hospitalizations with longer hospital stays, social isolation and depression
due to the inability to talk and eat, subsequent dose reductions,
treatment interruptions and discontinuations, and as a corollary to dose
reductions and treatment interruptions/discontinuations, diminished
antitumor responses and shorter survival. The economic consequences
are far from trivial as well with the incremental cost exceeding $17,000
(USD) for patients with head and neck cancer [23].
The cornerstone of management for the substantial pain and
ulceration, which results and which may persist even after treatment is
completed, are parenteral opioid analgesics that themselves carry the
inherent risk of aversive side effects such as constipation and
decreased alertness [24]. (Figure 2)
Pathogenesis
The pathogenesis of oral mucositis is thought to involve direct and
indirect mechanisms resulting from treatment with chemotherapy
and/or radiotherapy that interfere with the division and maturation of
epithelial cells.
a) Direct Mechanisms
The epithelial cells of the oral mucosa have a fast turnover rate,
usually every 7 to 14 days, which explains their direct susceptibility to
apoptosis from cytotoxic therapy and the onset of mucositis
approximately two weeks after chemotherapy initiation [25,26].
b) Indirect Mechanisms
Indirect toxic bystander effects that exacerbate the morbidity of
mucositis include the release of pro-inflammatory mediators such as
tumor necrosis factor (TNF), interleukin-1 beta (IL-1β) and IL-6
from activated M1 and N1 macrophages and neutrophils, with a
concomitant decrease in the anti-inflammatory cytokines IL-10 and
TGF-β that would normally act to dampen the inflammatory
response as well as secondary infection/colonization from/by
Gram-negative bacteria and fungal species. Oral infections also tend
to coincide with neutropenia.
Sonis has proposed a 5-stage model of mucositis, the importance of
which is that, while likely incomplete, it identifies potential
therapeutic targets (e.g. free radicals, pro-inflammatory cytokines,
infection) that could hinder or reverse the development of OM with
radio- and chemoprotectors. (See Table 3 and Figure 3)
Amifostine
a) Background
Initially under the auspices of the Manhattan Project during World
War II, a systematic screen of 4400 compounds was undertaken at
Walter Reed Army Research Institute to identify potential radio-
protectors, which culminated in the selection of WR-27213 (the
“WR” signifies Walter Reed) or Amifostine on the basis of its superioractivity and safety profile [28]. Renamed Ethyol after its acquisition
by MedImmune who later sold it to Astra Zeneca and now marketed
by Clinigen Group, a UK pharma company, as well as two generic
companies, Sun Pharma and Mylan Pharmaceuticals, amifostine has
been used and approved clinically to ameliorate the side effects of
chemotherapy and radiotherapy. Of the two FDA approvals, the first
was in 1996 to reduce the cumulative renal toxicity associated with
repeated administration of cisplatin in patients with advanced ovarian
cancer or non-small cell lung cancer; the second was in 1999 for
radiation-induced xerostomia in Head and Neck cancer [29].
Reportedly, amifostine was provided to the Apollo astronauts on
their trip to the Moon in case of exposure to solar flare radiation [30].
b) Mechanism and Toxicities
A phosphorylated aminothiol prodrug [31], amifostine is dephos-
phorylated by the enzyme, alkaline phosphatase that is at high levels in
normal tissues but at low levels in tumors and thus converted to its active
free radical-scavenging sulfhydryl metabolite,WR-1065, which provides
a selective mechanism for protection of non-CNS tissues (since
amifostine does not cross the blood brain barrier). Other mechanisms
for preferential protection of normal tissues include increased uptake in
the salivary glands and kidneys. As a free radical scavenger, amifostine
quenches DNA damaging species from ionizing radiation and alkylating
agents. (Figure 4) However, in animal studies it was observed that
amifostine diffuses into malignant tissues [32], albeit more slowly than
normal tissues, which raises a still-lingering question mark, even nearly
30 years after its approval, about the potential of amifostine to also
protect tumors from radiation and chemotherapy cytotoxicity. In
addition to this potential for tumor cytoprotection, its use in the clinic is
limited by severe toxicities such as emesis and hypotension.
Palifermin
a) Background
Palifermin or Kepivance is a recombinant human form of
Keratinocyte growth factor (KGF) originally derived from embryonic
lung fibroblasts and developed by Amgen that acts specifically on the
differentiation, proliferation and survival of epithelial cells, which
express the KGF receptor, throughout the GI tract [33]. In 2004, the
FDA approved the use of palifermin [34] to reduce the incidence and
duration of severe oral mucositis in patients with hematological
malignancies [35]. However, palifermin has not been approved for
use in head and neck cancers likely due a lack of improvement in
Figure 3. Illustration of the 5 phases of mucositis adapted from Sonis [65]
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ance despite a significant reduction in the severity and duration of oral
mucositis [36,37].
b) Mechanism and Toxicities
Palifermin binds to the KGF receptor [38], which induces the
differentiation of epithelial cells and mediates a host of biological effects
including upregulation of Th2 cytokines, inhibition of epithelial cell
apoptosis, prevention ofDNA strand breaks and tissue remodeling [39].Figure 4. Amifostine as a thiol-based free radical scavenger, which
prevents DNA damageWhile the FDA package insert [40]states under its Warnings and
Precautions section that palifermin is associated with the proliferation of
KGF-receptor bearing malignant cells as well as secondary cancers in
laboratory animals, a long term follow up of 672 patients treated with
palifermin or placebo (428 palifermin and 244 placebo) with a median
follow-up time of 7.9 years demonstrated no differences in the incidence
of secondary malignancies [41]. Palifermin is generally well tolerated
with mild-to-moderate adverse events of the skin and the mouth [42].
GC4419
a) Background
Excessive formation of reactive oxygen species such as superoxide
(SO) radical O2 plays a central role in the pathogenesis of mucositis.
The antioxidant enzyme superoxide dismutase (SOD) detoxifies
superoxides via transformation to the relatively stable and poorly
reactive oxidant, hydrogen peroxide (H2O2). However, during
radiation therapy, the overproduction of superoxide radicals so
overwhelms native SOD enzymes that SO-mediated damage results,
which suggest that exogenous administration of superoxide dismutase,
will reduce the toxicity of radiation and chemotherapy. Indeed, during
the 1970s, Orgotein, a Cu-Zn superoxide dismutase, was used
successfully to ameliorate radiation-induced toxicity in bladder tumors
[43]. However, use of SODs in the clinic has been limited by problems
of immunogenicity when derived from non-human sources, large size
(MW ~30,000) [44] and a short half-life, since they are prone to
hydrolysis in vivo, and therefore require continuous infusion [45].
As an alternative to these large unstable immunogenic proteins,
synthetic small molecule SODmimetics (SODm) have been developed.
One example of a non-peptide SODm is GC4419, a manganese-based
low molecular weight small molecule that selectively dismutates
superoxide anions but not other biologically relevant oxidizing species
Figure 5. Redox cycling of the catalytic metal, Mn, in GC4419
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phase 2b clinical trial with 223 head and neck cancer patients, GC4419
resulted in a 92% reduction in the duration of oralmucositis (P = 0.024)
and has received FDA fast track designation [46].
b) Mechanism and Toxicities
The selectivity of GC4419 for superoxide is due to the reduced
manganese (II) ion in the center of the molecule, which is alternately
reduced by superoxide anion to Mn (III) and re-oxidized to Mn (II)
by protonated superoxide via a one-electron pathway. Superoxide is
the only kinetically competent oxidant/reductant in the redox cycle of
Mn: Other one-electron radicals such as nitric oxide and oxygen are
too sluggish to oxidize Mn (II) while the more potent peroxynitrite,
hydrogen peroxide and hypochlorite, which transfer two electrons, are
not able to oxidize it [47]. (Figure 5)Figure 6. Schema of RRx-001-mediated oxidative preconditioninIn a Phase 1b/2a trial of GC4419 a maximum tolerated dose was
not reached and only two dose-limiting toxicities, grade 3
gastroenteritis and vomiting with hyponatremia, were observed [48].
One potential “toxicity” of GC4419 and all SOD mimetics
is tumor protection since antioxidants like SOD inhibit the
formation of free radicals, which are cytotoxic. However, because
GC4419 selectively dismutates superoxide into H2O2, which is
an oxidant in its own right, tumor inhibition is more likely than
tumor protection.
RRx-001
a) Background
Similar to amifostine, RRx-001 also originated in a military setting,
having been derived from 1,3,3-Trinitroazetidine or TNAZ, a melt cast
explosive [49]. Developed by EpicentRx, a San Diego, California-based
biotech, RRx-001 is under investigation in a Phase II clinical trial called
QUADRUPLE THREAT (NCT02489903) as a chemosensitizer of
platinum resistant/refractory small cell carcinoma and a high-grade
neuroendocrine carcinoma and as a radioprotector in case of nuclear
emergency at the Armed Forces Radiobiologic Research Institute
(AFRRI). Preliminary data from the QUADRUPLE THREAT trial
indicate that in 24 enrolled patients RRx-001 was associated with 4.2%
of Grade 3/4 neutropenia (1/24) and a 0% rate of febrile neutropenia
compared to a historical rate of neutropenia of 79.8% [50] and an 11%
rate of febrile neutropenia for platinum plus etoposide, which may be
indicative of bone marrow chemoprotection. Preclinical data also
provide evidence of radioprotection [51] and platinum chemoprotec-
tion [52] A Phase II proof of concept randomized chemoradioprotec-
tion trial for oral mucositis in head and neck cancer is in preparation and
scheduled to start at end of 2017 with three weekly doses of RRx-001
preceding the start of cisplatin and radiotherapy (RT) and continued
RRx-001 dosing during platinum + RT rest periods.g, resulting in potential chemoprotection and radioprotection
Translational Oncology Vol. 11, No. xx, 2018 Clinical Chemoradioprotection for Oral Mucositis Oronsky et al. 777b) Mechanism and Toxicities
The mechanism of chemoradioprotection is red blood cell-based,
since RRx-001 binds to and oxidatively modifies hemoglobin (Hb).
The result of Hb oxidation is deposition of iron and heme in the red
blood cell membrane with subsequent shedding of iron and lipid-laden
microvesicles in normal tissues as an RBC self-protection mechanism
against reactive oxygen species (ROS) accumulation. The deposition of
these Fenton-active microvesicles in healthy tissues such as the bone
marrow end induces a slight oxidative stress, which results in
upregulation of Nrf2-dependent antioxidant enzymes [53]. Similar to
ischemic preconditioning, first described in the dog myocardium [54],
whereby periods of ischemia and reperfusion prior to a prolonged period
of ischemia dramatically increases ischemic tolerance in solid organs
such as the heart, liver, kidney, and bones, this form of
RRx-001-mediated oxidative priming to induce the endogenous Nrf2
antioxidant machinery in normal cells preconditions them to better
withstand subsequent oxidative insults. As both a single agent and in
combination with radiation and chemotherapy, RRx-001 is well
tolerated and to date has not been associated with any dose-limiting
toxicities in over 200 treated patients [55]. (Figure 6)
Conclusion and Possible Future Directions
According to Sonis’ characterization, on whose model the current 5 step
pathogenesis of OM is based, mucositis is a toxicity that “largely defies
effective intervention” [56]. In light of the lack of progress to treat
it despite an extended clinical legacy, which reaches as far back as
Marie Curie’s discovery of radium in 1897 [8], and on the premise that
an ounce of prevention is worth a pound of cure, a chemo-and
radioprotection strategy would seem to make eminent sense.
Unfortunately, as a field, radio- and chemoprotection also carries a lot
of historical baggage, since its inception approximately 7 decades ago,
when the amino acid cysteine was identified as a putative radioprotector
in 1949 [57]. In all of this time, despite multiple potential candidates,
including antioxidants, plant extracts, antihypertensives, steroid
hormones, statins and cytokines [58], many of which have failed in
clinical trials due to acute toxicities [59,60], the only one to be approved
as both a chemo- and radioprotector is amifostine [61]; however, its
reputation and, by extension the whole chemo- and radioprotection
field of which amifostine serves as the prototype and standard bearer,
has suffered by virtue of its multiple toxicities including nausea,
vomiting and hypotension, underwhelming clinical outcomes and the
still-lingering possibility, to date never absolutely disproven, that
amifostine also protects tumors and reduces therapeutic gain [62].
Hence, these black marks on amifostine and the resultant shortfall
of candidates in clinical evaluation contribute to the impression that
chemoradioprotection is a therapeutic and commercial dead-end,
which, in turn, disincentivizes R&D and serves to establish a vicious
cycle of disinterest and disinvestment. However, the magnitude of the
unmet need in mucositis, absence of competition and potential
market of at least 500,000 plus patients per year [63], which is the
annual worldwide incidence of head and neck (H&N) cancer, since
almost all H&N patients receive loco-regional radiotherapy also
presents a high-reward opportunity for private sector investors
e.g., pharmaceutical companies and venture capital firms. In addition
to H&N cancer, a market also exists for patients treated with
commonly prescribed chemotherapeutic agents that are associated
with mucositis such as methotrexate, doxorubicin, 5-fluorouracil,
etoposide, cisplatin, and carboplatin.In terms of future directions, one potential strategy is to treat with a
cocktail of RRx-001, amifostine, palifermin, CG4419, which has
shown promise in the clinic, and potentially other agents as well such
as corticosteroids and hematopoietic factors on the premise that they
may act synergistically to protect normal tissues given their
non-overlapping mechanisms of action. Moreover, RRx-001, as a
chemoprotector as well as a radioprotector, may attenuate the
dose-limiting toxicities of amifostine. If successful, and anticancer
activity is not adversely affected, the immediate result will likely be a
paradigm shift from quantity of life to quality of life-centered
treatment where the same regimens are given with the same or better
efficacy but with considerably less toxicity.
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